2021 Volume 58 Issue 1 Pages 30-39
Necrotic enteritis caused by Clostridium perfringens has reemerged as a severe poultry disease worldwide since the ban on the routine use of antibiotics in animal feed. Probiotics are considered alternatives to antibiotic growth promoters. Bacillus species are the most common microorganisms used as probiotics in the feed industry. The current study investigated the growth and surfactin levels of Bacillus licheniformis in solid-state fermentation using different substrates and evaluated the effects of B. licheniformis-fermented products on growth performance and intestinal morphology in broilers exposed to C. perfringens. The highest viable biomass and surfactin concentration of B. licheniformis-fermented products was observed at 2% molasses and 20% soybean meal supplementation during fermentation (P<0.05). B. licheniformis-fermented product-derived surfactin inhibited the growth of C. perfringens in vitro in a dose dependent manner (P<0.05). B. licheniformis-fermented product supplementation (2 g/kg) significantly improved the body weight and average daily gain weight of broilers challenged with C. perfringens (P<0.05). B. licheniformis-fermented products significantly alleviated necrotic lesions and ameliorated intestinal morphology in broilers exposed to C. perfringens (P<0.05). Collectively, these observations demonstrate that B. licheniformis-fermented products improve growth performance and gut morphology in broilers under C. perfringens challenge. B. licheniformis-fermented products may have the potential to be used as alternatives to antibiotic growth promoters for preventive treatments against C. perfringens in broilers.
Necrotic enteritis is the most common enteric disease caused by Clostridium perfringens in poultry. Necrotic enteritis typically occurs in broilers that are 2 to 6 weeks of age and leads to sudden death (Songer, 1996; Timbermont et al., 2011). Clinical signs of necrotic enteritis include severe depression, bloody diarrhea, decreased appetite, and ruffled feathers. Lesions of necrotic enteritis are mostly prevalent in the small intestine. Subclinical necrotic enteritis manifests in broilers as poor growth performance without mortality (Van Immerseel et al., 2004; Cooper and Songer, 2010; Timbermont et al., 2011). Antibiotics in feed have been effective in controlling the prevalence of necrotic enteritis in broilers. However, the occurrence and severity of C. perfringens-induced necrotic enteritis has increased over the years due to the banning of the use of antibiotics in food-producing animals (Timbermont et al., 2011). Thus, the poultry industry is in urgent need of alternative strategies to prevent necrotic enteritis in broilers.
Probiotics have become the ideal alternative to antibiotic growth promoters. Prevention of C. perfringens-induced necrotic enteritis with the use of probiotics or probiotic derived metabolites has been increasingly studied (Knap et al., 2010; Abudabos et al., 2013; Cheng et al., 2018; Lin et al., 2019). Bacillus licheniformis, a gram-positive and endospore-forming probiotic strain exhibits in vitro antibacterial activity against C. perfringens through the production of the antibacterial cyclic lipopeptide surfactin (Thaniyavarn et al., 2003; Barbosa et al., 2005; Horng et al., 2019). Our previous studies have shown that surfactin isolated from B. licheniformis-fermented products can suppress the growth of C. perfringens, Brachyspira hyodysenteriae, and Staphylococcus aureus in vitro (Horng et al., 2019; Lin et al., 2019). Furthermore, B. licheniformis is able to mitigate C. perfringens-induced necrotic enteritis and ameliorate growth performance in broilers (Knap et al., 2010; Liu et al., 2012; Gong et al., 2018; Musa et al., 2019).
It has been reported that B. licheniformis-fermented products improve growth performance and diarrhea incidence in broilers and weaning piglets, respectively (Hung et al., 2019; Chen and Yu, 2020). B. licheniformis-fermented products also positively regulate the gut microflora composition of broilers and weaning piglets (Hung et al., 2019; Chen and Yu, 2020). It has been demonstrated that probiotics may exclude or reduce the growth of pathogens from the intestine through the alteration of the gut microbiota, thus preventing pathogen infection in broilers (Maki et al., 2019). Therefore, we hypothesized that B. licheniformis-fermented products might improve growth performance and gut morphology in broilers under C. perfringens challenge.
Our recent findings indicated that B. licheniformis-fermented products may be produced in solid-state fermentation and its antibacterial activities have been evaluated in vitro and in vivo (Horng et al., 2019; Lin et al., 2019). However, the growth performance was not significantly improved by B. licheniformis-fermented products in broilers under C. perfringens challenge (Lin et al., 2019). Compared with a recent study (Chen and Yu, 2020), the insufficient amount of B. licheniformis in fermented products may be the main reason for the results previously reported (Lin et al., 2019). In addition, we did not measure the surfactin levels in B. licheniformis-fermented products in the previous study (Lin et al., 2019). Thus, the viable biomass of B. licheniformis and antibacterial cyclic lipopeptide levels in B. licheniformis-fermented products still need to be optimized for its application in the poultry industry.
Therefore, we aimed to investigate the different substrates for solid-state fermentation for B. licheniformis growth and antibacterial cyclic lipopeptide production. We then studied the effect of different concentrations of B. licheniformis-fermented products on broilers challenged with C. perfringens. The findings provide valuable insights for the use of B. licheniformis-fermented products as a possible substitute for antibiotics in the poultry industry.
B. licheniformis (ATCC® 12713™) was purchased from BCRC (Food Industry Research and Development Institute, Hsinchu, Taiwan). B. licheniformis was thawed and inoculated into an Erlenmeyer flask containing tryptic soy broth (TSB; BD Biosciences, Sparks, MD, USA) and then incubated at 30°C for 18 h in a shaker at 150 rpm. Solid-state fermentation substrates, including glucose, molasses, soybean meal, wheat bran, yeast, fish meal, and potassium dihydrogen phosphate were ground to a fine powder with a grinder. Solid-state fermentation of B. licheniformis was optimized by investigating the effect of different concentrations of carbon (glucose and molasses, with 10% soybean meal used as the sole nitrogen source) and nitrogen sources (soybean meal, with 2% molasses used as the sole carbon source) on the bacterial count (colony forming unit, CFU) and surfactin production. Water was added into space bags to bring the initial moisture content of combined substrates up to 50%. The space bags containing solid-state fermentation substrates were autoclaved at 121°C for 30 min. The sterile fermentation substrates were inoculated with a 4% (v/w) B. licheniformis inoculum and cultured at 30°C with a relative humidity above 80% for 6 days in a chamber. The fermented products were dried in an oven at 50°C for 2 days and homogenized with a grinder. The fermented powder was then stored at 4°C until further use.
Determination of Bacterial Count and Surfactin ConcentrationThe fermented powder was serially diluted in 0.85% NaCl and incubated on tryptic soy agar plates (TSA; BD Biosciences) at 30°C for 18 h. B. licheniformis colonies were counted and expressed as colony forming units per gram (CFU/g). For surfactin extraction, the fermented powder was dissolved in 0.85% NaCl and centrifuged at 12,000×g for 20 min. The supernatant was adjusted to pH 2.0 with concentrated HCl and incubated overnight at 4°C. After centrifugation at 12,000×g for 20 min, the supernatant was discarded and the pellet was then dissolved in distilled water. The crude extracts containing surfactin were dialyzed and lyophilized. The lyophilized extracts were reconstituted in methanol and filtered through a 0.22 µm membrane using a syringe filter. High-performance liquid chromatography was performed to quantify surfactin concentration in the filtrate using the SPD-20A system with a programmable UV detector (20A VP, Shimadzu, Kyoto, Japan) and a reverse phase RP-18 column (LiChrospher 100 RP-18 endcapped, 5 µm, Merck, Temecula, CA, USA). The mobile phase consisted of 3.8 mM trifluoroacetic acid: acetonitrile (20:80, v/v). Surfactin concentration was determined with a UV detector at 210 nm. The flow rate and recorder were set to 1 mL/min and 30 min, respectively. A linear response was obtained over a range of 100–1000 µg/mL of the commercial surfactin standard (Sigma-Aldrich, St. Louis, MO, USA). The slope of the standard curve was used to determine the concentration of surfactin in fermented products.
Antibacterial Activity DeterminationThe antibacterial activity of B. licheniformis-fermented products was analyzed using an agar well diffusion assay. C. perfringens was a generous gift from Chung-Hsi Chou (Zoonoses Research Center and School of Veterinary Medicine, National Taiwan University, Taiwan) and was used as a bacterial pathogen indicator for the determination of the antibacterial activity. The detailed sampling and bacterial identification of C. perfringens from the field was reported in a previous study (Fan et al., 2016). Briefly, C. perfringens from intestinal samples of 5-week-old broilers with necrotic enteritis was isolated by streaking on tryptose sulfite cycloserine agar (TSC agar; Sigma-Aldrich) and blood agar plates and then incubated under anaerobic conditions at 37°C for 24 hr. The C. perfringens toxinotype from field isolates was identified by multiplex PCR reaction and determined as type A and NetB negative. The B. licheniformis-fermented product derived surfactin was serially diluted in 0.85% NaCl (concentration ranging from 7.8 to 250 µg/mL). Surfactin and ampicillin were separately transferred into wells in Gifu anaerobic medium agar (GAM agar; Sigma-Aldrich) containing C. perfringens and then cultured under anaerobic conditions at 37°C for 24 h. Inhibition zones were determined after incubation.
Animal StudiesOne-day-old healthy male broiler chicks (Ross 308) were purchased from a local commercial hatchery. On day 1, 60 chicks with an average body weight of 46.58±0.34 g were randomly allocated into 12 cages (4 groups×3 replications, each replication included 5 chicks) in a completely randomized design. Each group was assigned to one of the 4 experimental diets. Broilers were reared in stainless-steel, temperature-controlled cages (190 cm × 50 cm × 35 cm, width × length × height) with plastic-coated wire flooring. The experimental diets consisted of: (1) a basal diet plus C. perfringens challenge as control; (2) a basal diet plus C. perfringens challenge and 0.5 g/kg enramycin from days 1 to 21 and 1.2 g/kg enramycin from days 22 to 35; (3) a basal diet plus C. perfringens challenge and 1 g/kg of B. licheniformis-fermented products (2.5×108 CFU/g of feed); and (4) a basal diet plus C. perfringens challenge and 2 g/kg of B. licheniformis-fermented products (5.0×108 CFU/g of feed). The diets were formulated to meet or exceed the requirements of broilers according to the National Research Council recommendations (NRC 1994) (Table 1). Fish meal was included in the basal diets to increase the effect of C. perfringens challenge (Cooper and Songer, 2010). In the B. licheniformis-fermented product-treated groups, the soybean meal in the basal diet was replaced with B. licheniformis-fermented products at an equal amount. Feed and water were provided ad libitum throughout the experiment. The temperature was set at 32°C on the first day, gradually reduced to 24°C by the third week, and then maintained at 24°C up to the end of the experiment. The lighting schedule was 22L: 2D throughout the experiment. Vaccination of chickens with combined Newcastle disease-infectious bronchitis vaccines was performed on days 4 and 14 via nose drop administration. For the C. perfringens challenge, C. perfringens (toxinotype A and NetB negative) was grown anaerobically in brain heart infusion (BHI; Sigma-Aldrich, St. Louis, MO, USA) at 37°C overnight. The detailed sampling and bacterial identification of C. perfringens from the field was reported in a previous study (Fan et al., 2016). The birds were orally gavaged with 1 mL (1×108 CFU/mL) of an overnight culture of C. perfringens in BHI at 19, 20, and 21 days of age. Their growth performance, including average body weight, average daily gain weight, average daily feed intake, and feed conversion ratio, were recorded and calculated from days 1 to 35.
| Item | |
|---|---|
| Ingredient, g kg−1 | |
| Corn, yellow | 511.8 |
| Soybean meal, 36.7% CP | 350.0 |
| Fish meal | 100.0 |
| CaCO3, 38% | 20.0 |
| CaHPO4 | 10.0 |
| DL-Methionine, 99.5% | 2.0 |
| Choline chloride, 50% | 0.2 |
| Sodium chloride | 4.0 |
| Mineralpremix1 | 1.0 |
| Vitamin premix2 | 1.0 |
| Calculated value, g kg−1 | |
| Crude protein | 230.0 |
| Analyzed calcium | 13.8 |
| Analyzed total phosphorus | 7.0 |
| Lysine | 13.4 |
| Methionine + Cystine | 10.0 |
| ME, kcal/kg | 3411 |
On 22 and 35 days of age, three birds from each group (one bird per replicate) were randomly chosen and then euthanized using inhalation of carbon dioxide gas. Each intestinal segment (duodenum, jejunum, and ileum) from each bird was divided into three separate parts and then the lesion score evaluated. Lesion scores were observed and recorded according to a previous study (Al-Sheikhly and Truscott, 1977) (Fig. S1), where 0 is normal and 1 to 3 indicate the increasing severity of the infection. The scores were: 0=no lesions; 1=thin, friable walls, diffuse superficial, and removable fibrin deposit; 2=focal necrosis, ulceration, and non-removable fibrin deposit (1 to 5 foci); 3=focal necrosis, ulceration, and non-removable fibrin deposit (5 to 15 foci).
Small Intestinal Morphology AnalysisOn 22 and 35 days of age, three birds from each group (one bird per replicate) were randomly chosen and euthanized through inhalation of carbon dioxide gas. Three different locations in the small intestine were collected for morphology analysis: 2 cm after the gizzard (duodenum), before the Meckel's diverticulum (jejunum), and 2 cm before the ileo-caecal transition (ileum). These intestinal segments were fixed immediately in 10% (w/v) neutral-buffered formalin solution (Merck, Temecula, CA, USA) at 4°C. Formalin-fixed tissue was dehydrated in xylene, embedded in paraffin, sectioned (5 µm thickness and 6 cross-sections from each sample), and then stained with hematoxylin and eosin. The villus length and crypt depth from each segment were measured randomly in one bird (10 villi per intestinal segment) using light microscopy with a digital video camera (CKX41 microscope, Olympus Corporation, Tokyo, Japan). The stereological image software (Cast Image System, Visiopharm Albertslund, Hørsholm, Denmark) was used to analyze the images.
Quantitative Reverse Transcription-PCROn 22 and 35 days of age, three birds from each group (one bird per replicate) were randomly chosen and then euthanized through inhalation of carbon dioxide gas. Total RNA was extracted from spleens using the TRIzol Reagent extraction method (Invitrogen, Carlsbad, CA, USA) and quantified by spectrophotometry. Total RNA was reverse-transcribed using the One-Step RT-qPCR Reagents (Bio-Rad, Hercules, CA, USA) and gene expression (inos, cox2, ifnγ, il-1β, β-actin) was measured using the MiniopticonTM Real-Time PCR Detection System (Bio-Rad) and the iTaq Universal SYBR Green Supermix (Bio-Rad). The β-actin gene was used as a reference to normalize gene expression in the same sample. The primers were as follows: inos forward: 5′-AGG CCA AAC ATC CTG GAG GTC-3′, and reverse: 5′-TCA TAG AGA CGC TGC TGC CAG-3′; cox2 forward: 5′-AAC ACA ATA GAG TCT GTG ACG TCT T-3′, and reverse: 5′-TAT TGA ATT CAG CTG CGA TTC GG-3′; ifnγ forward: 5′-ACA CTG ACA AGT CAA AGC CGC ACA-3′, and reverse: 5′-AGT CGT TCA TCG GGA GCT TGG C-3′; il-1β forward: 5′-CAG CCT CAG CGA AGA GAC CTT-3′, and reverse: 5′-CAC TGT GGT GTG CTC AGA ATC C-3′; β-actin forward: 5′-CAT CAC CAT TGG CAA TGA GAG G-3′, and reverse: 5′-GGT ACA TTG TGG TAC CAC CAG AC-3′.
Ethics StatementAll experiments were conducted according to the approved guidelines of the advisory group on the ethics of animal experiments at the National Ilan University (IACUC, protocol number 107-12).
Statistical AnalysisData were tested for normality and subjected to a one-way analysis of variance using the general linear models procedure of SAS software package (Version 9.4; SAS Institute, Cary, NC). Linear and quadratic contrasts were used to determine the effects of different concentrations of B. licheniformis-fermented product on broilers. A Turkey's honestly significant difference test was carried out with P< 0.05. Treatments were considered significantly different at P<0.05.
Solid-state fermentation of B. licheniformis was optimized by investigating the effect of the combination of substrates on growth and surfactin production. The carbon source analysis showed an increased bacterial growth with the supplementation of 2% molasses compared with the other substrates (Table 2; P<0.05). An increasing trend in surfactin levels was observed with the supplementation of 2% molasses compared with 2% glucose (Table 2). However, 2% molasses supplementation increased surfactin levels more than the 1% supplementation (Table 2; P<0.05). The nitrogen source analysis showed that a 20% soybean meal supplementation produced the highest bacterial growth and surfactin levels compared with the other substrates (Table 3; P<0.05). Furthermore, the agar well diffusion assay showed that surfactin derived from B. licheniformis-fermented products had a concentration-dependent inhibitory effect on the growth of C. perfringens (Table 4; P<0.05).
| B. licheniformis-fermented products | ||
|---|---|---|
| Total viable count (CFU/g)2 | Surfactin (mg/g) | |
| 2% glucose1 | 6.4×109±1.2×109,b | 5.78±0.78ab |
| 1% molasses | 7.2×109±0.2×109,b | 4.29±0.56b |
| 2% molasses | 1.3×1011±0.5×1010,a | 6.22±0.69a |
Different letters indicate a statistically significant difference between groups (P<0.05).
| B. licheniformis-fermented products | ||
|---|---|---|
| Total viable count (CFU/g)2 | Surfactin (mg/g) | |
| 5% soybean meal1 | 3.1×1011±2.1×1010,c | 5.72±0.46c |
| 10% soybean meal | 4.7×1011±1.6×1010,b | 6.48±0.34c |
| 20% soybean meal | 8.3×1011±5.9×1010,a | 9.75±0.323a |
| 30% soybean meal | 4.3×1011±0.4×1010,b | 8.30±0.65b |
Different letters indicate a statistically significant difference between groups (P<0.05).
| Concentration (µg/mL) | Zone of inhibition (cm)1 |
|---|---|
| 7.8 | 0.3±0.01a |
| 15.61 | 0.3±0.01a |
| 31.25 | 0.4±0.01b |
| 62.5 | 0.5±0.02b |
| 125 | 0.7±0.04c |
| 250 | 0.9±0.02d |
Different letters indicate a statistically significant difference between groups (P<0.05).
The effect of dietary B. licheniformis-fermented product supplementation on the growth performance of broilers under C. perfringens challenge is shown in Table 5. After the C. perfringens challenge, the supplementation of enramycin in the feed of chickens increased their body weight at 21 days of age compared with other treatments (P<0.05). The dietary supplementation of 2 g/kg of B. licheniformis-fermented products in broilers also increased their body weight at 21 days of age compared with the control group (P<0.05). Similar results were also found in broilers at 35 days of age (P< 0.05). Broilers fed enramycin had a higher average daily weight gain between days 1 and 21 and this was also significant over the whole trial period (days 1 to 35) compared with other treatments (P<0.05). The supplementation of 2 g/kg of B. licheniformis-fermented products in the feed of chickens also resulted in a significant increase in the average daily weight gain between days 1 and 21 and this was also significant over the whole trial period (days 1 to 35) compared with the control group (P<0.05). No significant difference was found in the average daily feed intake among groups. The supplementation of enramycin in the feed of chickens resulted in a significantly reduced feed conversion ratio between days 1 and 21 compared with the control group (P<0.05). Similarly, the supplementation of the broiler diet with B. licheniformis-fermented products (1 and 2 g/kg) also decreased feed conversion ratio between days 1 and 21 (P<0.05). Broilers supplemented with enramycin had a lower feed conversion ratio over the whole trial period (days 1 to 35) compared with other treatments (P<0.05). Although the effect was not statistically significant, B. licheniformis-fermented products showed a similar trend in ameliorating the feed conversion ratio of broilers between days 22 and 35 and the whole trial period. No chickens died in the experiment.
| C1 | E2 | L3 | H4 | SEM | P value | |
|---|---|---|---|---|---|---|
| Body weight (g/bird) | ||||||
| 1 d | 46.335 | 46.47 | 46.90 | 46.60 | 0.10 | 0.373 |
| 21 d | 759.27a | 902.67c | 825.93b | 850.80b | 16.46 | <0.001 |
| 35 d | 1682.93a | 1870.67c | 1735.84ab | 1787.03bc | 22.44 | 0.003 |
| Average daily gain (g/d/bird) | ||||||
| 1–21 d | 33.95a | 40.77c | 37.10b | 38.30b | 0.78 | <0.001 |
| 22–35 d | 65.98 | 69.14 | 64.99 | 66.87 | 0.70 | 0.258 |
| 1–35 d | 46.76a | 52.12c | 48.26ab | 49.73bc | 0.64 | 0.003 |
| Average daily feed intake (g/d/bird) | ||||||
| 1–21 d | 52.38 | 52.83 | 49.21 | 51.24 | 0.78 | 0.427 |
| 22–35 d | 156.19 | 137.78 | 144.13 | 151.87 | 2.97 | 0.148 |
| 1–35 d | 93.90 | 86.81 | 87.17 | 91.49 | 1.39 | 0.255 |
| Feed conversion ratio | ||||||
| 1–21 d | 1.54a | 1.30b | 1.33b | 1.34b | 0.03 | 0.005 |
| 22–35 d | 2.37 | 1.99 | 2.23 | 2.28 | 0.06 | 0.123 |
| 1–35 d | 2.01a | 1.67b | 1.81ab | 1.84ab | 0.04 | 0.034 |
Different letters indicate a statistically significant difference between groups (P<0.05).
The effect of dietary B. licheniformis-fermented product supplementation on the intestinal lesion score of broilers under C. perfringens challenge is shown in Table 6. After 22 days of feeding, enramycin treatment efficiently mitigated the duodenal and jejunal damage caused by C. perfringens compared with the control group (P<0.05). Similar to the effect of enramycin, the dietary supplementation of 2 g/kg of B. licheniformis-fermented products relieved the C. perfringens-induced necrotic lesions in the duodenum and jejunum of broilers (P<0.05). After feeding the diets for 35 days, broilers fed with enramycin and B. licheniformis-fermented products (1 and 2 g/kg) had significantly reduced lesion scores in the jejunum compared with the control group (P<0.05). Enramycin mitigated the C. perfringens-induced necrotic lesions in the ileum of broilers compared with the control group (P<0.05). The effect of dietary B. licheniformis-fermented product supplementation on the morphology of the small intestine of broilers under C. perfringens challenge is shown in Table 7 and Fig. S2. Enramycin and B. licheniformis-fermented products (1 and 2 g/kg) had a similar significant effect in improving villus length in the duodenum and jejunum at 21 days of age (P<0.05). No significant difference was found in the intestinal crypt depth among groups. The ratio of villus length to crypt depth was increased in the duodenum in broilers fed with enramycin and B. licheniformis-fermented products (1 and 2 g/kg) at 21 days of age compared with the control group (P<0.05). Although the effect was not statistically significant, B. licheniformis-fermented products (1 and 2 g/kg) showed a similar trend in increasing the ratio of villus length to crypt depth in the jejunum at 21 days of age. After 35 days, broilers supplemented with enramycin and B. licheniformis-fermented products (1 and 2 g/kg) had longer villus in the jejunum and ileum compared with the other treatments (P<0.05). B. licheniformis-fermented products (2 g/kg) reduced the jejunal and ileal crypt depth at 35 days of age compared with the other treatments (P<0.05). The ratio of villus length to crypt depth was increased in the jejunum and ileum in broilers fed with enramycin and 2 g/kg of B. licheniformis-fermented products at 35 days of age compared with the other treatments (P<0.05). The effect of dietary B. licheniformis-fermented product supplementation on mRNA expression in spleens of broilers under C. perfringens challenge is shown in Table 8. Results showed that inos mRNA expression was not altered among groups in broilers of 22 days of age. The cox2 mRNA expression was higher in broilers fed with B. licheniformis-fermented products (1 and 2 g/kg) compared with the enramycin group (P<0.05). B. licheniformis-fermented products (2 g/kg) significantly increased the ifnγ and il-1β mRNA expression in broilers of 22 days of age compared with the control group (P<0.05). Enramycin significantly reduced the ifnγ mRNA expression in broilers of the same age compared with the control group (P<0.05). After 35 days of feeding, the inos mRNA expression was induced in broilers fed with B. licheniformis-fermented products (1 g/kg) (P<0.05). B. licheniformis-fermented products (1 and 2 g/kg) significantly induced the il-1β mRNA expression in broilers of 35 days of age compared with the control group (P<0.05).
| C1 | E2 | L3 | H4 | SEM | P value | |
|---|---|---|---|---|---|---|
| 22 d | ||||||
| Duodenum | 2.785,a | 1.67b | 2.22ab | 1.78b | 0.12 | 0. 008 |
| Jejunum | 2.33a | 1.56ab | 2.00ab | 1.22b | 0.15 | 0.039 |
| Ileum | 2.22 | 1.22 | 1.89 | 1.44 | 0.12 | 0.111 |
| 35 d | ||||||
| Duodenum | 2.33 | 1.78 | 2.22 | 1.56 | 0.11 | 0.173 |
| Jejunum | 2.67a | 1.89b | 1.44b | 1.22b | 0.12 | 0.002 |
| Ileum | 2.44a | 1.67b | 2.22ab | 1.89ab | 0.13 | 0.033 |
Different letters indicate a statistically significant difference between groups (P<0.05).
| C1 | E2 | L3 | H4 | SEM | P value | ||
|---|---|---|---|---|---|---|---|
| 22 d | |||||||
| Villus length (µm) | Duodenum | 437.935,a | 939.67bc | 859.40b | 1099.70c | 75.84 | <0.001 |
| Jejunum | 402.23a | 880.90b | 957.40b | 844.17b | 72.48 | <0.001 | |
| Ileum | 396.30a | 647.23ab | 714.20b | 520.43ab | 44.74 | 0.031 | |
| Crypt depth (µm) | Duodenum | 266.90 | 193.00 | 163.70 | 189.83 | 15.28 | 0.081 |
| Jejunum | 194.60 | 168.50 | 162.17 | 129.80 | 14.32 | 0.415 | |
| Ileum | 185.23 | 155.17 | 179.30 | 144.70 | 9.74 | 0.421 | |
| Villus length: Crypt depth | Duodenum | 1.73a | 4.88b | 5.34b | 5.89b | 0.52 | 0.004 |
| Jejunum | 2.15 | 5.33 | 6.36 | 7.54 | 0.77 | 0.063 | |
| Ileum | 2.17 | 4.21 | 4.25 | 3.59 | 0.34 | 0.100 | |
| 35 d | |||||||
| Villus length (µm) | Duodenum | 608.03 | 878.40 | 755.97 | 823.87 | 69.95 | 0.402 |
| Jejunum | 455.90a | 983.63c | 1013.87c | 721.27b | 73.47 | <0. 001 | |
| Ileum | 529.77a | 799.10b | 805.13b | 684.13b | 38.37 | 0.001 | |
| Crypt depth (µm) | Duodenum | 201.03 | 181.67 | 156.77 | 174.67 | 11.11 | 0.573 |
| Jejunum | 286.33a | 198.90ab | 182.60ab | 130.00b | 23.10 | 0.030 | |
| Ileum | 147.50ab | 139.97ab | 160.90a | 100.43b | 8.58 | 0.038 | |
| Villus length: Crypt depth | Duodenum | 3.02 | 5.51 | 4.81 | 4.68 | 0.54 | 0.320 |
| Jejunum | 1.69a | 5.01b | 5.56b | 6.11b | 0.58 | 0.004 | |
| Ileum | 3.59a | 5.94b | 5.02ab | 6.79b | 0.40 | 0.013 |
Different letters indicate a statistically significant difference between groups (P<0.05).
| C1 | E2 | L3 | H4 | SEM | P value | |
|---|---|---|---|---|---|---|
| 22 d | ||||||
| inos5 | 1.06 | 0.3 | 0.8 | 1.0 | 0.10 | 0.057 |
| cox2 | 1.0ab | 0.2a | 1.7b | 1.6b | 0.21 | 0.002 |
| ifnγ | 1.0c | 0.1d | 1.6b | 2.1a | 0.22 | <0.001 |
| il-1β | 1.0b | 2.1ab | 2.9ab | 3.6a | 0.35 | 0.017 |
| 35 d | ||||||
| inos | 1.0b | 0.5b | 2.2a | 1.1b | 0.19 | 0.001 |
| cox2 | 1.0ab | 0.4b | 1.1ab | 1.4a | 0.14 | 0.036 |
| ifnγ | 1.0ab | 0.8b | 1.3ab | 1.4a | 0.09 | 0.002 |
| il-1β | 1.0b | 1.5ab | 2.5a | 2.5a | 0.23 | 0.022 |
Different letters indicate a statistically significant difference between groups (P<0.05).
The results of linear and quadratic dose-response of dietary B. licheniformis-fermented products on broilers challenged with C. perfringens are shown in Table 9. The B. licheniformis-fermented product concentration was linearly correlated with the body weight, average daily weight gain, and lesion score in broilers under C. perfringens challenge (P<0.05). Besides, the concentration of B. licheniformis-fermented products was linearly correlated with the villus length and the ratio of villus length to crypt depth in broilers of 22 days of age, particularly in the duodenum and jejunum (P<0.05). The crypt depth and the ratio of villus length to crypt depth were linearly associated with the B. licheniformis-fermented product concentration in broilers of 35 days of age, particularly in the jejunum and ileum (P<0.05). The quadratic dose-response of dietary B. licheniformis-fermented products was also found in the villus length of jejunum and ileum in broilers of 22 and 35 days of age (P<0.05).
| Item | P value | |||||
|---|---|---|---|---|---|---|
| B. licheniformis-fermented product concentration1 | Growth performance | Linear | Quadratic | |||
| Body weight | 0.007 | 0.975 | ||||
| Average daily gain | 0.007 | 0.988 | ||||
| Average daily feed intake | 0.590 | 0.145 | ||||
| Feed conversion ratio | 0.130 | 0.197 | ||||
| Lesion score | ||||||
| 22 d | Duodenum | 0.002 | 0.783 | |||
| Jejunum | 0.003 | 0.326 | ||||
| Ileum | 0.018 | 0.822 | ||||
| 35 d | Duodenum | 0.023 | 0.258 | |||
| Jejunum | 0.002 | 0.029 | ||||
| Ileum | 0.064 | 0.822 | ||||
| Intestinal morphology | ||||||
| 22 d | Villus length | Duodenum | <0.001 | 0.144 | ||
| Jejunum | 0.039 | 0.010 | ||||
| Ileum | 0.382 | 0.009 | ||||
| Crypt depth | Duodenum | 0.127 | 0.092 | |||
| Jejunum | 0.180 | 0.999 | ||||
| Ileum | 0.216 | 0.618 | ||||
| Villus length: Crypt depth | Duodenum | 0.003 | 0.047 | |||
| Jejunum | 0.018 | 0.353 | ||||
| Ileum | 0.155 | 0.068 | ||||
| 35 d | Villus length | Duodenum | 0.337 | 0.844 | ||
| Jejunum | 0.222 | 0.001 | ||||
| Ileum | 0.174 | 0.008 | ||||
| Crypt depth | Duodenum | 0.183 | 0.029 | |||
| Jejunum | 0.021 | 0.615 | ||||
| Ileum | 0.033 | 0.002 | ||||
| Villus length: Crypt depth | Duodenum | 0.224 | 0.417 | |||
| Jejunum | 0.007 | 0.106 | ||||
| Ileum | < 0.001 | 0.566 | ||||
Solid-state fermentation is considered to be cheaper and more environmentally friendly than submerged fermentation for the production of value-added fermented products (Teng et al., 2017; Su et al., 2018; Lima-Pérez et al., 2019). Our previous study found that the highest viable B. licheniformis biomass (4×108 CFU/g) was observed at 5% glucose, 10% soybean meal, and 3% yeast after 6 days of solid-state fermentation (Lin et al., 2019). Recently, it has been reported that B. licheniformis bacterial growth and polysaccharide production was increased in molasses-based submerged fermentation (Gojgic-Cvijovic et al., 2019). However, it has not been proven that molasses could be used as the sole carbon source for the optimization of the solid-state fermentation of B. licheniformis. Besides, the macro molecules of soybean are efficiently degraded to low molecular weight compounds using B. licheniformis during solid-state fermentation (Kiers et al., 2000). In this study, we modified the solid-state fermentation conditions for B. licheniformis and further demonstrated that replacing 5% glucose with 2% molasses as the sole carbon source and increasing soybean meal concentration from 10% to 20% might increase the number of B. licheniformis (8.3×1011 CFU/g) after 6 days of solid-state fermentation. The concentration of surfactin in B. licheniformis-fermented products was also quantified in the present study. Interestingly, replacing glucose with molasses might increase B. licheniformis growth during solid-state fermentation, but the concentration of surfactin in fermented products was not significantly elevated using molasses as the sole carbon source. A previous study reported that the lower growth rate of cell biomass due to nutritional limitations in solid-state fermentation may trigger the synthesis of surfactin (Shaligram and Singhal, 2010). These results imply that B. licheniformis growth is not highly correlated with the production of surfactin during solid-state fermentation. Here, B. licheniformis-fermented products also exhibited similar antibacterial activity against C. perfringens compared with our previous studies (Horng et al., 2019; Lin et al., 2019). Collectively, replacing glucose with molasses and increasing the soybean meal concentration during solid-state fermentation may increase the growth of B. licheniformis. This fermentation conditions may be suitable for their application in industrial-scale solid-state fermentation in the future.
Over the past decades, it has been demonstrated that the dietary supplementation of probiotics in broilers can provide similar benefits as antibiotics in terms of growth performance and disease prevention (Abudabos et al., 2017; Abudabos et al., 2020). However, previous studies mainly used probiotics as feed additives for the improvement of broiler production. The application of B. licheniformis-fermented products obtained from solid-state fermentation in the poultry industry is rarely investigated. Our previous study showed that B. licheniformis-fermented products have similar benefits as antibiotics on the improvement of growth performance and diarrhea incidence in broilers and weaning piglets, respectively (Hung et al., 2019; Chen and Yu, 2020). In this study, we further demonstrated that 2 g/kg of B. licheniformis-fermented products might ameliorate growth performance and improve gut morphology in broilers challenged with C. perfringens. The gut microbiota is important for the optimal growth and disease prevention in broilers. It has been demonstrated that B. licheniformis-fermented products also positively regulate the broiler gut microbiota composition (Chen and Yu, 2020). Whether B. licheniformis-fermented products ameliorate the growth performance of broilers exposed to C. perfringens challenge by altering the gut microflora needs to be further investigated. These findings indicate that the dietary supplementation of B. licheniformis-fermented products show beneficial effects in improving growth performance and preventing disease in broilers.
Necrotic enteritis is the most common and serious bacterial disease in broilers. C. perfringens-induced necrotic enteritis causes severe necrosis of intestinal mucosa, leading to impaired nutrient utilization and reduced growth performance (Van Immerseel et al., 2004; Cooper and Songer, 2010; Timbermont et al., 2011). Previous studies reported that dietary B. licheniformis supplementation reduce the intestinal lesion score and mortality in broilers exposed to C. perfringens (Knap et al., 2010; Musa et al., 2019; Zhao et al., 2019). It has been proposed that B. licheniformis may prevent necrotic enteritis by preventing proliferation of C. perfringens, promoting the death of C. perfringens, or eliminating the effect of the toxins produced by C. perfringens. Our recent finding showed that B. licheniformis-fermented product-derived antibacterial cyclic lipopeptide surfactin might cause the death of C. perfringens and suppress the growth of C. perfringens in vitro (Horng et al., 2019). Here, we further demonstrated that B. licheniformis-fermented products containing surfactin reduced intestinal necrotic lesions and ameliorated gut morphology in broilers challenged with C. perfringens to the same level as in the antibiotic-treated group. Compared to previous studies (Knap et al., 2010; Musa et al., 2019; Zhao et al., 2019), the B. licheniformis-fermented products generated from solid-state fermentation contain live microorganisms, B. licheniformis-derived surfactin, and fermented substrates. Thus, the efficiency of B. licheniformis-fermented products on the alleviation of C. perfringens-induced necrotic enteritis in broilers may be different compared to previous studies. Whether supplementation of surfactin alone in the diet prevents the mortality and necrotic enteritis in broilers exposed to C. perfringens remains to be further investigated. Collectively, these findings indicated that the dietary supplementation of B. licheniformis-fermented products exhibited the potential for the prevention of C. perfringens-induced necrotic enteritis in broilers.
In a previous study, we determined that the body weight of the non-infected control group and the infected group at 35 days of age was 1.90 kg and 1.76 kg, respectively (Cheng et al., 2018). Here, the body weight of the infected group and the enramycin-treated group was 1.68 kg and 1.87 kg at 35 days of age, respectively; however, there is no non-infected control group in the present study. These results partially support that C. perfringens challenge cause a negative impact on the broiler body weight, whereas the enramycin treatment alleviates the adverse effect on the body weight. In the present study, the feed conversion ratio of the infected group was higher than in the enramycin-treated group (2.01 versus 1.67). In addition, the enramycin treatment was able to alleviate the intestinal lesion score and improve the intestinal morphology of broilers exposed to C. perfringens compared with the infected group. These results may indicate that necrotic enteritis was successfully developed in broilers under the C. perfringens challenge.
In conclusion, the highest viable biomass of B. licheniformis and surfactin levels were observed at 2% molasses in combination with 20% soybean meal during solid-state fermentation. We demonstrated for the first time that 2 g/kg of B. licheniformis-fermented products potentially improved growth performance and intestinal morphology in broilers exposed to C. perfringens. Thus, B. licheniformis-fermented products may be useful feed additives replacing banned infeed antibiotics.
This work was supported by the Ministry of Science and Technology (MOST 107-2321-B-197-002 and MOST 108-2321-B-197-001) in Taiwan.
The authors declare no conflict of interest.
